Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,188 signal articles · 242 in last 24h · 120,076 total before filter · latest 41m ago
242last 24h
1438last 7d
242● bullish (7d)
155● bearish (7d)
205publishers
AllMacro258Earnings542M&A100Regulatory19Product11Analyst22
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Johnson Controls International (JCI) After Q3 Earnings Is The Upside Still Priced In
Simply Wall St.18d agoneutral
Johnson Controls International (JCI) After Q3 Earnings Is The Upside Still Priced In

Why Johnson Controls International stock is in focus after Q3 earnings Johnson Controls International (JCI) is back on investors’ radar after its third quarter earnings release for the period ended June 30, 2026, highlighted fresh revenue and earnings figures across its building solutions portfolio. The company reported third quarter revenue of US$6.61b compared to US$6.05b a year earlier, with net income of US$749m compared to US$701m. Basic and diluted earnings per share from continuing...

Is Nextpower (NXT) Undervalued On Record Revenue And Higher 2027 Guidance?
Simply Wall St.18d agoneutral
Is Nextpower (NXT) Undervalued On Record Revenue And Higher 2027 Guidance?

Nextpower (NXT) is back in focus after reporting record first quarter revenue, expanding its backlog above US$5.5b, and raising fiscal 2027 guidance for both revenue and GAAP net income. See our latest analysis for Nextpower. Despite the earnings beat, raised fiscal 2027 outlook, and a backlog above US$5.5b, Nextpower’s share price has pulled back sharply in recent weeks. The 30 day share price return is down 20.36% and the 90 day share price return is down 25.06%, even as the 1 year total...

How Q2 2026 Earnings Beat And Premium Growth At Delta Air Lines (DAL) Has Changed Its Investment Story
Simply Wall St.18d agobullish
How Q2 2026 Earnings Beat And Premium Growth At Delta Air Lines (DAL) Has Changed Its Investment Story

Delta Air Lines recently reported second-quarter 2026 earnings of US$1.56 per share, topping consensus estimates despite higher fuel costs and revenue coming in slightly below expectations, while premium and diversified revenue streams continued to expand. Analysts have responded to this performance with upgraded earnings estimates and a strong consensus rating, highlighting growing confidence in Delta’s ability to leverage premium, loyalty, and international revenue to support its profit...

Morgan Stanley's Amazon earnings verdict has a blind spot
TheStreet18d agoneutral
Morgan Stanley's Amazon earnings verdict has a blind spot

Amazon (AMZN) stock closed the July 31 trading session up 15.32% at $271.58, as it soared following the release of its second quarter (Q2) 2026 earnings report on July 30. The stock is up 17.66% year-to-date as of Saturday morning, August 1. Meanwhile, the SPDR S&P 500 index (SPY) is up about ...

Colgate Palmolive (CL) Stock Trades At A Cash Flow Discount Despite An Earnings Premium
Simply Wall St.18d agoneutral
Colgate Palmolive (CL) Stock Trades At A Cash Flow Discount Despite An Earnings Premium

Colgate-Palmolive stock has delivered a 30.8% return over the past five years, yet there is a split in what the valuation tools say today. The Discounted Cash Flow (DCF) intrinsic value estimate points to upside relative to the market price, while traditional market multiples suggest the shares are on the expensive side. Over the last 5 years Colgate-Palmolive has returned 30.8%, which points to a steady but not spectacular payoff for long term holders. The key support for the current...

5 Insightful Analyst Questions From Nasdaq’s Q2 Earnings Call
StockStory18d agoneutral
5 Insightful Analyst Questions From Nasdaq’s Q2 Earnings Call

Nasdaq’s second quarter was marked by double-digit growth across all divisions, as the company benefited from robust demand for its market infrastructure and technology solutions. Management highlighted historic milestones in listings, including the SpaceX IPO and record net inflows in its Index business, as well as the growing adoption of AI-enabled tools. CEO Adena Friedman pointed to the breadth of new client activity and product launches as key contributors, while ongoing investment in digit

The 5 Most Interesting Analyst Questions From Intel’s Q2 Earnings Call
StockStory18d agoneutral
The 5 Most Interesting Analyst Questions From Intel’s Q2 Earnings Call

Despite exceeding Wall Street’s estimates for both revenue and non-GAAP profit, Intel’s second quarter results prompted a significant negative market reaction. Management pointed to record demand for server CPUs, robust data center performance, and improving manufacturing execution as key drivers of the period. CEO Lip-Bu Tan highlighted, “Our core server CPU franchise is growing faster than ever,” and emphasized progress in Intel’s advanced packaging and foundry offerings. However, the company

5 Must-Read Analyst Questions From Sallie Mae’s Q2 Earnings Call
StockStory19d agoneutral
5 Must-Read Analyst Questions From Sallie Mae’s Q2 Earnings Call

Sallie Mae’s second-quarter performance fell short of Wall Street’s expectations, with both revenue and GAAP earnings per share missing analyst forecasts. Management attributed the flat revenue and lower profits to a combination of increased noninterest expenses—mainly from upfront investments in new products and technology—and a temporary dip in net interest margin due to elevated liquidity ahead of peak loan origination season. CEO Jonathan Witter emphasized that credit trends within the portf

Iovance Biotherapeutics (IOVA) Heads Into Earnings With Its T Cell Therapy Story And Valuation In Focus
Simply Wall St.19d agoneutral
Iovance Biotherapeutics (IOVA) Heads Into Earnings With Its T Cell Therapy Story And Valuation In Focus

Iovance Biotherapeutics (IOVA) is drawing attention ahead of its second quarter 2026 earnings report and corporate update scheduled for August 6, 2026, which will be presented alongside its first FDA-approved T cell therapy for solid tumors. See our latest analysis for Iovance Biotherapeutics. The latest pullback in Iovance Biotherapeutics, with a 1-day share price return down 13.22% and 7-day share price return down 18.44% to US$4.07, sits against a stronger backdrop that includes a 30-day...

Chubb (CB) Could Be 4% Undervalued On Q2 2026 Earnings
Simply Wall St.19d agoneutral
Chubb (CB) Could Be 4% Undervalued On Q2 2026 Earnings

Chubb (CB) has drawn fresh attention after reporting second quarter 2026 results, with net income of US$2.854b and earnings per share broadly in line with the same period a year earlier. See our latest analysis for Chubb. Chubb shares have eased in the past week, with a 7 day share price return of 2.52% down. However, the year to date share price return of 13.1% and 1 year total shareholder return of 32.82% point to momentum that has built over a longer stretch. If Chubb's recent move has you...

5 Must-Read Analyst Questions From Comcast’s Q2 Earnings Call
StockStory19d agoneutral
5 Must-Read Analyst Questions From Comcast’s Q2 Earnings Call

Comcast’s second quarter results were marked by a mix of progress and ongoing challenges, with the company surpassing Wall Street’s revenue and profit expectations but facing a negative market reaction. Management highlighted steady gains in wireless services, which delivered record net line additions and increasing premium plan uptake. However, softness in domestic broadband, where subscriber losses persisted despite improved customer satisfaction, remained a concern. CEO Brian Roberts pointed

The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call
StockStory19d agoneutral
The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call

West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response remained muted. Management attributed the outperformance to robust growth in its Proprietary Products, particularly high-value product (HVP) components for biologics and biosimilars. CEO Eric Green highlighted, “Our performance was driven by the execution of our strategy and continued operational excellence initiatives,” pointing to the compan

PepsiCo (PEP): Buy, Sell, or Hold Post Q2 Earnings?
StockStory19d agoneutral
PepsiCo (PEP): Buy, Sell, or Hold Post Q2 Earnings?

Over the past six months, PepsiCo’s shares (currently trading at $144.08) have posted a disappointing 6.2% loss, well below the S&P 500’s 7.1% gain. This may have investors wondering how to approach the situation.

Delta (DAL) Stock Looks Cheap On Earnings But Pricey After 125% Return
Simply Wall St.19d agoneutral
Delta (DAL) Stock Looks Cheap On Earnings But Pricey After 125% Return

Delta Air Lines stock has delivered a strong 124.7% return over the past 5 years, yet today's mixed valuation checks leave investors weighing how much upside is already reflected in the current US$87.44 share price. Over 5 years, a 124.7% total return suggests the market has already reassessed Delta Air Lines more positively and may now be more sensitive to changes in expectations. Recent headlines about United Airlines having explored a merger with Delta Air Lines highlight how...

Did AngloGold Ashanti’s (AU) Earnings Surge, Buyback, and Dividend Hike Just Recast Its Investment Narrative?
Simply Wall St.19d agobullish
Did AngloGold Ashanti’s (AU) Earnings Surge, Buyback, and Dividend Hike Just Recast Its Investment Narrative?

In the first half of 2026, AngloGold Ashanti plc reported net income of US$2.28 billion, roughly double the prior-year period, alongside higher earnings per share, a new US$2.00 billion share buyback program, an interim dividend of US$0.72 per share, and reaffirmed full-year production guidance despite slightly lower gold output. This combination of stronger profitability, increased cash returns through dividends and buybacks, and steady production guidance underlines management’s focus on...

Bloomberg19d agoneutral
AI Isn’t a Catch-All Trade for Stocks in This Earnings Season

(Bloomberg) -- Equity investors are learning a harsh lesson this corporate earnings season: Not all artificial intelligence trades are created equal.Most Read from BloombergSingapore's Gated Island for the Rich Is Marred by Decayed HomesMoonshot’s Kimi Uses 20,000 Nvidia Chip Cluster From AlibabaTrump Orders Iran Attack as Soon as This Weekend, WSJ SaysAnthropic AI Models Hacked Three Organizations During TestsVitol, Cargill Cut Ties With Radiant World Amid Fake Invoice ConcernsWhile profits at